Stocks in news: Adani Power, JSW Energy, IndiGo, Cipla, Religare

GQG Partners Emerging Market Fund bought 10,284,024 shares or 0.6% stake in JSW Energy at Rs 341.70 apiece for Rs 351 crore.

ETMarkets.com
Lupin said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solution used to treat post-operative inflammation in patients who have undergone cataract surgery.
Nifty futures traded 18 points, or 0.09 per cent, lower at 19,394, signaling that Dalal Street was headed for a negative start on Thursday. Here's a slew of stocks that will be in focus today for various reasons.

Adani Power
GQG Partners along with other investors picked up 8.1% in Adani Power in a $1.1 billion deal.

JSW Energy
GQG Partners Emerging Market Fund bought 10,284,024 shares or 0.6% stake in JSW Energy at Rs 341.70 apiece for Rs 351 crore.


Read more: What changed the market while you were sleeping

IndiGo

The family of IndiGo's co-founder Rakesh Gangwal has sold partial stake in the budget carrier through bulk deals on Wednesday.

Cipla
The FDA, Konkan Division, has ordered for suspension of FDA license issued to the company's manufacturing unit at Patalganga (Unit II) for a period of 10 days in December 2023 for non-conformance of good manufacturing practices.

ADVERTISEMENT
Religare Enterprises
Investment Opportunities fund has sold 2.45 crore shares in the company through block deals on Wednesday.

IIFL Securities
Hamblin Watsa Investment Counsel has sold 1.2 crore shares or 3.9% stake in IIFL Securities in a block deal on Wednesday.

Future Retail
The resolution professional of Future Retail has approached NCLT, seeking a further extension till September 15 to complete the corporate insolvency resolution process of the debt-ridden firm.

Amara Raja Batteries
Amara Raja Batteries plans to expand into the two-wheeler electric vehicle market, first through chargers and then batteries, as part of an expansion to triple its lithium-ion business this financial year.

ADVERTISEMENT
Lupin
Lupin said it has received approval from the US health regulator to market its generic Bromfenac Ophthalmic Solution used to treat post-operative inflammation in patients who have undergone cataract surgery.


ADVERTISEMENT
READ MORE

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › Markets › Stocks › News › Stocks in news: Adani Power, JSW Energy, IndiGo, Cipla, Religare
Text Size:AAA
Success
This article has been saved

*

+